The Clinical Frontier · 4 October 2026 · Issue 018 How frontier AI and open models land in real clinical workflows, for India’s health-IT community.
In this issue
- Google’s MedGemma 1.5 (released January 2026) is an open medical vision-language model that supports ophthalmology, CT, MRI, and histopathology, available commercially on Vertex AI.
- A startup called Visilant has already fine-tuned it on 200,000 eye images to build a smartphone screening system for eye care access in India.
- For India’s more than 90 million adults with diabetes, about 1 in 5 carrying some degree of diabetic retinopathy, this stack is the practical foundation for district-level screening at a cost the public health system can actually reach.
The signal
Google released MedGemma 1.5 on 13 January 2026 as an update to its open collection of medical vision-language foundation models. The 4B multimodal version expanded support for three-dimensional imaging (CT and MRI volumes), whole-slide histopathology images, longitudinal chest X-ray comparisons, and ophthalmology, training on an extended collection of retinal fundus images. The model is available for research and commercial use on Google Cloud Vertex AI and HuggingFace (google/medgemma-1.5-4b-it).
Alongside it, Google released MedASR, a speech-to-text model trained specifically for medical language. On Google’s internal benchmarks, MedASR produces significantly fewer transcription errors than a general-purpose speech recognition model on medical dictation, where a wrong drug name or dosage carries clinical weight.
Both models are described in the MedGemma 1.5 blog post from Google Research.
One India example already shipping
Visilant, a startup focused on expanding eye care access in India, fine-tuned MedGemma 1.5 4B on a specialised dataset of 200,000 eye images and domain-specific knowledge. The result is a smartphone-based screening system that can detect conditions affecting visual health, expanding eye care access across India.
Visilant’s work is documented in Google’s own Health AI Developer Foundations showcase. It is not a research paper. It is a working product built on an open Google model, already oriented toward India’s access gap.
How it actually works
MedGemma 1.5 is a collection of three model variants: 4B multimodal, 27B text-only, and 27B multimodal. All multimodal versions use a SigLIP image encoder trained on de-identified medical data. For ophthalmology, the model is trained for image classification tasks including diabetic retinopathy detection.
A team building a DR screening app does not train from zero. They:
- Start from MedGemma 1.5 4B multimodal weights, which already encode retinal anatomy from the expanded ophthalmology training dataset.
- Fine-tune on a locally held, de-identified dataset of graded fundus images, with significantly less data than building a model from scratch.
- Deploy the fine-tuned model on a local server or edge device, with no dependency on an external API.
MedASR runs separately as a speech model, accepting medical dictation and returning accurate transcripts for clinical notes, referral letters, and encounter records.
Why India needs this, now
India has more than 90 million adults living with diabetes, the second-largest diabetic population globally after China (IDF Diabetes Atlas). The International Diabetes Federation estimates that approximately 1 in 5 people with diabetes in India has some degree of diabetic retinopathy, and 1 in 10 has the vision-threatening form that requires laser photocoagulation or intravitreal injection to prevent blindness.
That is a population requiring annual fundus screening. The clinical standard is one screening encounter per year for every diabetic. India’s ophthalmology workforce, concentrated in tier-one cities and medical colleges, cannot reach that volume in rural districts and peri-urban primary health centres without AI-assisted grading.
Today, many DR screening camps work like this: images are captured, sent to a grader in a city, and results returned days later. The patient who needed an urgent referral is long gone, back to their village, and the delay costs them their vision. An on-device AI model that grades the image at the moment of capture collapses that latency to zero.
The DPDP and data-residency fit
Under India’s Digital Personal Data Protection Act 2023, clinical images are personal data. Sending a fundus image to an external cloud API for grading is an act of data transfer that requires a valid legal basis, consent in a prescribed form, and potentially a data processing agreement with the cloud provider. On-device or on-premise inference sidesteps all of that: the image never leaves the health facility.
MedGemma’s open weights mean the fine-tuned model can run entirely inside the screening device or a local server at the primary health centre, with zero data egress. This is not just a nice property. For NHM-funded screening programs and state health departments, it is the difference between a legally simple deployment and a programme that needs a lawyer before it can start.
An ABDM-linked screening workflow
A practical district-level AI-assisted DR screening camp:
- Capture. An ophthalmic assistant attaches a smartphone fundus adaptor and photographs both fundus images.
- Instant grade. The on-device fine-tuned MedGemma model grades DR severity at the point of capture: no DR, mild, moderate, severe, or proliferative.
- Dictated note. MedASR transcribes the screener’s spoken summary directly into the patient encounter record.
- Referral routing. Mild grades receive a printed recall slip for next year. Severe or proliferative grades trigger an immediate referral to the nearest vitreoretinal service, logged in the health record.
- Registry linkage. All encounters, grades, and referrals are written to the patient’s ABHA-linked health record, building a longitudinal DR registry for district health planning and NHA monitoring.
No cloud call. No data leaving the district. No waiting for a grader in a city.
The takeaway
MedGemma 1.5 is not a finished product. It is an open foundation model with a clear primary source from Google and a verified India deployment example from Visilant. What it means for public health in India:
- The model pretraining is already done and given away. The hard compute and data cost has been paid by Google.
- Fine-tuning on local data is feasible for a district hospital network or NIN programme, with significantly less labelled data than training a model from scratch.
- Deployment behind the firewall is the architecture, not a constraint. DPDP compliance is built in.
- MedASR reduces workflow friction at the point of screening, which is usually the bottleneck in camp-based settings.
The screening gap in India is real and large. The model infrastructure to close it now exists, is free to use, and has already been deployed by an India-focused startup. The remaining work is building the fine-tuning datasets, the integration with ABDM health records, and the camp logistics to reach the 1 in 5 diabetics who do not yet know they have retinopathy.
The Clinical Frontier is a daily briefing from HCITExperts for India’s health-IT community. Primary sources: MedGemma 1.5 model card, MedGemma 1.5 and MedASR announcement, Visilant India showcase, IDF Diabetes Atlas 2024. More tomorrow.